Home/Biosimilar Atlas/Adalimumab/Reliance Life Sciences adalimumab

Reliance Life Sciences adalimumab

Adalimumab biosimilar developed by Reliance Life Sciences. Reference product Humira.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Reliance Life Sciences · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOJun 2015permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
AdalimumabmoleculeReliance Life Sciencesdeveloper1 of 7markets0trials behind it13other products, same developer4rival developers in its markets

About Reliance Life Sciences adalimumab

Reliance Life Sciences received its adalimumab permission in India in June 2015, the second Indian company to do so after Zydus. The Indian regulator records the firm and the molecule but not the brand name, so the product is listed here under the company's name. Reliance holds more biosimilar permissions than any other Indian company in the Atlas.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Reliance Life Sciences Pvt Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Jun 2015
Application or permission
MF-150/2015; BULK-149/2015
Indications as licensed
RA, JIA, PsA, AS and axial SpA, Crohn's disease, UC
Presentations
20 mg and 40 mg PFS (50 mg/mL)
Source
S014 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Reliance Life Sciences adalimumab holds an approval, these are the other adalimumab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO4Enzene Biosciences (Enzene Biosciences adalimumab), Hetero (Mabura), Shilpa Biologicals (Shilpa Biologicals adalimumab), Zydus Lifesciences (Exemptia / Cadalimab)

Same developer, other molecules

Other biosimilars in the Atlas developed by Reliance Life Sciences: Reliance Life Sciences bevacizumab, Reliance Life Sciences darbepoetin alfa, Reliance Life Sciences denosumab, Reliance Life Sciences etanercept, Reliance Life Sciences follitropin alfa, Reliance Life Sciences golimumab, Reliance Life Sciences infliximab, Reliance Life Sciences omalizumab, Reliance Life Sciences ranibizumab, Reliance Life Sciences rituximab, Reliance Life Sciences somatropin, Reliance Life Sciences trastuzumab, UstekiRel.

Chronology

Sources

All adalimumab biosimilars

Planning adalimumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.